stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) Operating cash flow
Amylyx Pharmaceuticals, Inc.'s operating cash flow for fiscal 2025 was −$123.3M, compared with −$167.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$126.6M. Over the past ten years it has ranged from −$179.9M (fiscal 2022) to $11.9M (fiscal 2023); the current reading is higher than 50% of that period. Amylyx Pharmaceuticals, Inc. ranks 83rd of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$123.3M | — |
| FY2024 | −$167.6M | — |
| FY2023 | $11.9M | — |
| FY2022 | −$179.9M | — |
| FY2021 | −$74.8M | — |
| FY2020 | −$36.7M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$31.4M | — |
| Mar 2026 | −$36.9M | — |
| Dec 2025 | −$27.9M | — |
| Sep 2025 | −$30.4M | — |
| 19 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| HIMS Hims & Hers Health, Inc. compare | $263.5M |
| TRLV Trulieve Cannabis Corp. compare | $242.5M |
| PRGO Perrigo Company plc compare | $240.6M |
| PBH Prestige Consumer Healthcare Inc. compare | $229.8M |
| LQDA Liquidia Corporation compare | $167.7M |
| SUPN Indivior Pharmaceuticals Inc. compare | $96.0M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$124.8M |
| AMLX Amylyx Pharmaceuticals, Inc. | −$126.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on AMLX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement